|Mr. Gabriele Marco Antonio Cerrone M.B.A., MBA||Founder & Exec. Chairman||13.76M||N/A||1972|
|Dr. Kunwar Shailubhai||CEO, Chief Scientific Officer & Exec. Director||810k||N/A||1958|
|Dr. Andrea Brancale||Scientific Founder||N/A||N/A||N/A|
|Mr. Richard Clarkson Ph.D.||Scientific Founder||N/A||N/A||N/A|
|Mr. Andrew Westwell Ph.D.||Scientific Founder||N/A||N/A||N/A|
|Ms. Keeren Shah||Fin. Director||N/A||N/A||1977|
|Dr. Thomas H. Adams Ph.D.||Head of Drug Devel. & Exec. Director||N/A||N/A||1943|
|Dr. Neil Graham M.D., M.P.H., MBBS, MPH||Chief Medical Officer||N/A||N/A||1959|
|Dr. Napoleone Ferrara||Chairman of Scientific Advisory Board||N/A||N/A||1958|
|Prof. Roberto Pellicciari||Consultant||N/A||N/A||N/A|
Tiziana Life Sciences plc, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology, inflammation, and infectious diseases. Its lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. The company is also developing Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients. It has a collaboration agreement with FHI Clinical to conduct a Phase 2 clinical trials for treating hospitalized severe COVID-19 patients with intranasal foralumab. The company was incorporated in 1998 and is based in London, the United Kingdom.
Tiziana Life Sciences PLC’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.